The aim of this study was to assess the antitumour response and @entity1054 ( @entity1054 ) of @entity1 treated with @entity2213 (Glivec, Gleevec, formerly @entity2213 ) who had advanced and/or metastatic @entity5 ( @entity5 ) or other soft tissue @entity242 (STS). @entity1 with measurable lesions and adequate organ function were entered. They were treated with @entity2213 at the dose of 400 mg twice daily (bid). All @entity5 were subject to a stringent pathological review by an expert panel. Immunohistochemical expression of @entity2467 expression was evaluated. A total of 51 @entity1 (27 @entity5 , 24 other STS), median age 53 years, median World Health Organization (WHO) performance score 1, were entered. 71% of the @entity1 had received prior chemotherapy. The most frequent side-effects were @entity417 (92%), periorbital @entity4 (84%), @entity1910 (69%), @entity1295 (76%), @entity390 (57%), @entity3028 (47%) and @entity294 (47%). Most of these side-effects were mild to moderate and no @entity1 was taken off study due to side-effects. @entity1910 and periorbital @entity4 frequently seem to be self limiting, despite continued treatment. In @entity5 @entity1 , the current response rates (RRs) are 4% complete remission (CR), 67% partial remission (PR), 18% @entity66 ( @entity66 ) and 11% progression ( @entity1726 ). 73% of @entity5 @entity1 are free from progression at 1 year. In the other STS group, there were no objective responses. The median @entity1054 in this subgroup was only 58 days. @entity2213 is well tolerated at a dose of 400 mg bid. This dose is active in @entity1 with @entity2467 -positive @entity5 , but @entity1 with other STS subtypes unselected for a molecular target are unlikely to benefit.

XXXX ( @entity2213 Glivec, Gleevec) is an active agent for @entity5 , but does not yield responses in other soft-tissue @entity242 that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

@entity1 :: ('9606', 'Species') :: ['patient', 'Patients', 'patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['skin rash', 'Skin rash'] @entity5 :: ('MESH:D009369', 'Disease') :: ['gastrointestinal stroma tumours', 'tumours', 'GIST'] @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity66 :: ('MESH:D004194', 'Disease') :: ['SD', 'stable disease'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD'] @entity2467 :: ('3815', 'Gene') :: ['KIT'] @entity3028 :: ('MESH:D000380', 'Disease') :: ['granulocytopenia'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['time to progression', 'TTP'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['Imatinib mesylate', 'STI-571', 'imatinib mesylate']
@entity2213 :: (MESH:C097613,Chemical) :: ['Imatinib mesylate']
